FDA Puts CytoDyn Clinical Trials For HIV, COVID-19 On Hold

CytoDyn Inc. (OTCQB: CYDY) reported on Wednesday that its current trials for investigational drug leronlimab will be put on partial hold for its HIV program and full hold on its COVID-19 program. While the firm did not disclose the reason behind the pause, it said it is “committed to [US Food and Drug Administration] compliance.”

“We are evaluating our clinical programs and are working to resolve the issues underlying the clinical holds as soon as possible in close communication with the FDA,” said Chief Medical Officer Dr. Scott Kelly. “We will provide an update when we have additional information.”

Leronlimab is a humanized monoclonal antibody targeted against a specific receptor in a human’s T-cell to trigger an immune system response. The FDA previously granted the firm a fast track designation to use the candidate drug as a possible treatment for HIV-related diseases and metastatic cancer.

The drug is also being studied by the biotech firm as an antibody treatment for critically ill COVID-19 patients, the study of which was in phase 3.

The clinical holds will mean the firm would have to pause enrolling new patients in the trials being conducted. For patients with HIV under its program, the firm plans to transition them to other therapeutics.

Meanwhile, the pause on its COVID-19 program means no new clinical studies will be initiated until the hold is resolved. This also includes pausing the Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting.

The biotech firm said it intends to work with FDA to resolve the clinical holds as soon as possible.

CytoDyn last traded at $0.475 on the OTCQB.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Gold is Up 30%, But the Real Bull Market is Only Starting Now! | Adrian Day

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Related News

Three Things to Know About ‘Phase 3 COVID Player’: Revive Therapeutics

Bucillamine Just Got Cleared for Phase 3 Trials of COVID-19 On Friday, July 31, 2020...

Monday, August 3, 2020, 10:11:55 AM

CytoDyn Files Legal Actions Against Its Former Contract Research Organization

CytoDyn Inc. (OTCQB: CYDY) announced this morning that it has filed a legal complaint about...

Thursday, October 7, 2021, 03:39:00 PM

CytoDyn Is Ready To Welcome Back The Former Chief Medical Officer It Terminated

It seems CytoDyn Inc. (OTCQB: CYDY) is ready to extend an olive branch to its...

Tuesday, May 24, 2022, 10:59:00 AM

CytoDyn Begins Phase 3 Trial Of Antibody Treatment For Critically Ill COVID-19 Patients

CytoDyn Inc. (OTCQB: CYDY) reported this morning that it has started its phase 3 clinical...

Monday, October 25, 2021, 10:59:00 AM

CytoDyn Starts Phase 3 Trial Of Antibody Treatment For COVID-19 Patients With Severe Symptoms In Brazil

CytoDyn Inc. (OTCQB: CYDY) reported on Thursday night that it started a phase 3 clinical...

Friday, September 10, 2021, 09:34:00 AM